Alembic Pharmaceuticals on Friday stated its consolidated web revenue declined by 19 per cent to Rs 133 crore for the second quarter ended September 2022 on account of upper bills.
The drug maker had reported a web revenue of Rs 164 crore within the July-September interval of final fiscal.
Income from operations rose to Rs 1,475 crore within the September quarter as towards Rs 1,292 crore within the year-ago interval, Alembic Pharmaceuticals stated in a regulatory submitting.
Bills in the course of the interval beneath assessment stood at Rs 509 crore as in comparison with Rs 428 crore earlier.
“It was a passable quarter led by development in all of the verticals of the corporate, specifically the API enterprise outperformed with a 23 per cent development in the course of the quarter,” Alembic Pharmaceuticals Managing Director Pranav Amin stated in a regulatory submitting.
Shares of the corporate on Friday ended 3.68 per cent up at Rs 638.75 apiece on the BSE.
(Solely the headline and movie of this report might have been reworked by the Enterprise Customary employees; the remainder of the content material is auto-generated from a syndicated feed.)
